Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C9 Antibodies (55) and CYP2C9 Proteins (4) and many more products for this protein.
Showing 4 out of 24 products:
Genetic polymorphisms in CYP2C9 cause significant interindividual variability in the metabolism of its substrates. This study estimated the coefficient of variation (CV) for the intrinsic hepatic clearance of tolbutamide by CYP2C9 for each CYP2C9 genotype using previously reported area under the blood concentration curve (AUC) and oral clearance (CLoral) values in a Monte Carlo simulation with a dispersion model.
These results suggest that genetic polymorphisms of CYP2C9 enzymes result in the production of varying levels of biologically active JWH-018 metabolites in some individuals, offering a mechanistic explanation for the diverse clinical toxicity often observed following JWH-018 abuse.
genetic association studies in population in China: Data suggest that SNPs in CYP2C9 and CYP2A6 are associated with hepatotoxicity due to antiepileptic drug valproate in the population studied. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2A6 = cytochrome P450 family 2 subfamily A member 6)
Studied the association of CYP2C9*2 (430C/T), *3 (1075A/C) and VKORC1 (show VKORC1 ELISA Kits) (-1639G/A) polymorphisms on warfarin dose requirements in patients post cardiac valve surgery. Found age and presence of CYP2C9 *2 allele significantly affect the daily dosage of warfarin during initiation of warfarin therapy after cardiac valve replacement surgery.
CYP2C9 mutations had a significant impact on 2-propyl-4-pentenoic acid concentration
We compared the carrier frequency of Cytochrome P450 Enzymes and Transport Proteins markers among the Russian population living in Moscow with Dagestan ethnic groups. Statistically significant differences for the following gene polymorphisms: CYP2C19*17, CYP2C9*3, ABCB1 (C3435T), SLCO1B1*5 were found between the Russian population and the three ethnic groups of the Dagestan republic.
Angiotensin II receptor blockers exhibit different degrees of inhibition of the metabolism of arachidonic acid by recombinant CYP2C9, CYP2J2 (show CYP2J2 ELISA Kits) and liver microsomes.
analysis of VKORC1 (show VKORC1 ELISA Kits) AA-CYP2C9*1*1 genotypes reveals dosing algorithms for vitamin K antagonists
In Silico Predictions of Drug - Drug Interactions Caused by CYP1A2 (show CYP1A2 ELISA Kits), 2C9 and 3A4 Inhibition - a Comparative Study of Virtual Screening Performance
To investigate whether the CYP2C9*2 and *3 variants modify benzodiazepine-related fall risk. CYP2C9*2 and *3 allele variants modify benzodiazepine-related fall risk. Those using benzodiazepines and having reduced CYP2C9 enzyme activity based on their genotype are at increased fall risk.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P-450 S-mephenytoin 4-hydroxylase
, cytochrome P-450MP
, cytochrome P450 2C9
, cytochrome P450 PB-1
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase